Myasthenia Gravis - Epidemiology Forecast - 2034

Myasthenia Gravis - Epidemiology Forecast - 2034

Key Highlights

DelveInsight’s analyst projects that among the total diagnosed prevalent cases of myasthenia gravis in 7MM approximately 45% of cases were from the US. As per our estimations, in 2023, the EU4 and the UK accounted for nearly 125 thousand diagnosed prevalent cases of myasthenia gravis.

According to the analysis conducted by DelveInsight, Myasthenia Gravis was diagnosed in approximately 52% of females and 48% of males within the 7MM in 2023. This analysis indicates a higher prevalence of myasthenia gravis among females than males.

The highest proportion of myasthenia gravis cases was estimated in the 65 years and above age group in the 7MM, with an estimated 151 thousand cases, while the least cases were in the age group 0-17 years (10 thousand cases).

DelveInsight’s “Myasthenia Gravis – Epidemiology – 2034” report delivers an in-depth understanding of the myasthenia gravis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Disease Understanding and Treatment Algorithm

Myasthenia Gravis Overview

According to the Muscular Dystrophy Association, myasthenia gravis is an autoimmune disease when the immune system attacks the body’s tissues. In myasthenia gravis, that attack interrupts the connection between nerve and muscle—the neuromuscular junction.

The most common target of pathogenic autoantibodies in myasthenia gravis is the nicotinic acetylcholine receptor (AChR), followed by a muscle-specific kinase (MuSK) and lipoprotein receptor-related protein 4 (LRP4). Myasthenia gravis presents with painless, fluctuating, fatigable weakness involving specific muscle groups. The most typical initial presentation includes ocular weakness with asymmetric ptosis and binocular diplopia, while the less common presentation includes early or isolated oropharyngeal or limb weakness.

Myasthenia Gravis Diagnosis

The clinical diagnosis of Myasthenia gravis is confirmed by electromyography (EMG) studies, pharmacologic testing, and serum Ab assay. Positive results on EMG confirm a postsynaptic defect of the NMT, the clinical response to cholinesterase inhibitors (ChE-Is) supports myasthenia gravis diagnosis, and detection of specific Abs confirms myasthenia gravis and identifies Ab-related subgroups. EMG confirmation is crucial in patients with neither AChR nor MuSK Abs on the standard assay.

Further details related to diagnosis are provided in the report…

Myasthenia Gravis Epidemiology

As the market is derived using the patient-based model, the Myasthenia Gravis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Myasthenia Gravis, Gender-specific Diagnosed Prevalent cases of Myasthenia Gravis, Age-specific Diagnosed Prevalent cases of Myasthenia Gravis, Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA classification, Diagnosed Prevalent Cases of Generalized Myasthenia Gravis by Antibody Serology in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per DelveInsight’s estimations, the total diagnosed prevalent cases of Myasthenia Gravis in the 7MM were approximately 287 thousand cases in 2023 and are projected to increase during the forecast period.

The overall count of individuals diagnosed with myasthenia gravis in the United States was approximately 129 thousand in 2023, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).

Among the 7MM, EU4 and the UK accounted for nearly 125 thousand diagnosed prevalent cases of myasthenia gravis, and these cases are expected to increase during the forecast period (2023-2034).

Among EU4 and the UK, Germany had the highest diagnosed prevalent population of myasthenia gravis, with 39 thousand cases, followed by the UK and France in 2023. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2023.

In Japan, there were around 32 thousand diagnosed prevalent cases of myasthenia gravis in 2023. These cases are expected to increase at a significant CAGR.

Gender-specific diagnosed prevalent cases of myasthenia gravis showed that females were more affected by myasthenia gravis than males in the 7MM in 2023.

The highest proportion of myasthenia gravis cases was estimated in the 65 years and above age group in the 7MM, while the least cases were in the age group 0-17 years.

Based on MGFA classification, diagnosed prevalent cases of myasthenia gravis were categorized into five classes: Class I (ocular), Class II (mild generalized), Class III (moderate generalized), Class IV (severe generalized), and Class V (intubated). A higher number of cases were estimated in Class II, with 56 thousand cases in 2023 in the US.

The antibody serology-specific cases of generalized myasthenia gravis were divided into anti-AchR Ab (+ve), anti-MuSK Ab (+ve), and double seronegative (anti-LRP4-ab and anti-Argin-ab) and others. In 2023, there were more cases estimated in the AchR Ab (+ve) category, with nearly 73 thousand cases reported in the United States.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on myasthenia gravis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from University of California, UCSF Medical Center, San Francisco; Department of Neurology, University of Virginia, Charlottesville, Virginia, USA; Department of Neurology, Kamillus-Hospital, Asbach, Germany; Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; Department of Neurology, National Hospital Organization, Nagasaki Kawatana Medical Center, Nagasaki, Japan, and others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Myasthenia Gravis, explaining its causes, signs and symptoms, and pathogenesis.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Myasthenia Gravis Report Insights

Patient Population

Country-wise Epidemiology Distribution

Diagnosed Prevalence of Myasthenia Gravis

Gender-specific Diagnosed Prevalence of Myasthenia Gravis

Age-specific Diagnosed Prevalence of Myasthenia Gravis

Severity-specific Diagnosed Prevalence of Myasthenia Gravis by MGFA classification

Antibody Serology of Generalized Myasthenia Gravis

Myasthenia Gravis Report Key Strengths

11 years Forecast

The 7MM Coverage

Myasthenia Gravis Epidemiology Segmentation

Key Questions

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of Myasthenia Gravis? What will be the growth opportunities across the 7MM concerning the patient population of Myasthenia Gravis?

What is the historical and forecasted Myasthenia Gravis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Why do only limited patients appear for diagnosis?

Which country is more prevalent for Myasthenia Gravis and why?

What factors are affecting the diagnosis of the indication?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Myasthenia Gravis prevalence cases in varying geographies over the coming years.

A detailed overview of Severity, Gender, and Age-specific prevalence of Myasthenia Gravis.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Myasthenia Gravis Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Myasthenia Gravis cases in 2023?

The highest cases of Myasthenia Gravis was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Myasthenia Gravis cases in 2023?

The highest cases of Myasthenia Gravis were found in the US among the 7MM in 2023.